1-(8-(2-Chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide (CP-945,598) is an orally active antagonist of the cannabinoid CB-1 receptor that progressed into phase 3 human clinical trials for the treatment of obesity. In this study, we investigated the metabolic fate and disposition of CP-945,598 in rats, Tg-RasH2 mice, and dogs after oral administration of a single dose of [ 14 C]CP-945,598. Total mean recoveries of the radioactive dose were 97.7, 97.8, and 99.3% from mice, rats, and dogs, respectively. The major route of excretion in all three species was via the feces, but on the basis of separate studies in bile duct-cannulated rats and dogs, this probably reflects excretion in bile rather than incomplete absorption. CP-945,598 underwent extensive metabolism in all three species, because no unchanged parent compound was detected in the urine across species. The primary metabolic pathway of CP-945,598 involved N-deethylation to form an N-desethyl metabolite (M1). M1 was subsequently metabolized by amide hydrolysis, oxidation, and ribose conjugation to numerous novel and unusual metabolites. The major circulating and excretory metabolites were species-dependent; however, several common metabolites were observed in more than one species. In addition to parent compound, M1, M3, M4, and M5 in rats, M1, M3, and M4 in mice, and M1 and M2 in dogs were identified as the major circulating metabolites. Gender-related differences were also apparent in the quantitative and qualitative nature of the metabolites in rats. An unprecedented metabolite, M4, formed by deamidation of M1 or M3 (N-hydroxy-M1), but not by decarboxylation of M2, was identified in all species. M4 was nonenzymatically converted to M5.
Introduction
Obesity is one of the greatest public health challenges of the 21st century, with 60.5% of the adult population overweight and 23.9% obese in the United States (Richard and Boisvert, 2006) . Overweight and obese people carry a higher risk for a variety of cardiovascular diseases including hypertension, type 2 diabetes, coronary heart disease, stroke, and peripheral occlusive artery disease. In industrialized countries, 2 to 10% of the total health care budget is spent on costs associated with obesity. The rising prevalence of obesity and its ramifications have prompted the exploration of several therapeutic strategies including serotonin and noradrenaline inhibitors, lipase inhibitors, B3-adrenoreceptor agonists, leptin agonists, and melanocortin-3 agonists. However, their use has been limited due to the presence of adverse events and patients' inability to retain weight loss once therapy is discontinued.
The endocannabinoid system (ECS) is a complex physiological system that comprises the cannabinoid receptor, endocannabinoids, and the enzymes involved in endocannabinoid synthesis and degradation. The ECS is believed to play a pivotal role in energy homeostasis, modulating food intake and fat metabolism (Richard and Boisvert, 2006 ). The ECS is expressed both in the brain and in peripheral tissues, and its stimulation influences metabolic pathways that lead to weight gain, lipogenesis, and impaired glucose homeostasis (Di Marzo and Matias, 2005; Kirkham, 2005) . Blockade of the CB1 receptor decreases food intake and induces weight loss in mouse and rat (Rinaldi-Carmona et al., 1994; Arnone et al., 1997; Colombo et al., 1998; Hildebrandt et al., 2003; Vickers et al., 2003; Black 2004; Di Marzo and Matias, 2005; Wiley et al., 2005) . Therefore, CB1 receptor antagonists might provide effective therapy options for the management of metabolic disorders, such as obesity (Di Marzo, 2008) .
1-(8-(2-Chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide 598 ) is an orally active antagonist of the cannabinoid CB-1 receptor that progressed into phase 3 human clinical trials for the treatment of obesity (Griffith et al., 2009; Ragan et al., 2009; Hadcock et al., 2010) . In vitro pharmacologic profiling indicated that it is a selective, high-affinity, and competitive CB-1 receptor antagonist that inhibits both basal and cannabinoid agonist-mediated CB-1 receptor signaling in vitro and in vivo (Hadcock et al., 2010) . It reduces acute food intake in rodents, decreases food intake and body weight in obese beagle dogs, and acutely stimulates energy expenditure in rats (Hadcock et al., 2010) . mmol) followed by concentrated aqueous HCl (1.59 ml, 19.1 mmol), dropwise. A solution of KCN (934 mg, 19 .1 mmol) in water (4.75 ml) was added to the heterogeneous reaction mixture, dropwise, and the mixture was then warmed to room temperature. After stirring for 2 days, ethanol (30 ml) was added, and the precipitated solid was collected by filtration, washed with 1:1 waterethanol (175 ml), and then dried, in vacuo, to give 2 as a colorless solid (4.95 g, 84%): ϩAPCI MS, m/z 306.4 (MH ϩ ).
Step 2. To a stirred heterogeneous mixture of 2 (4.95 g, 14.5 mmol) in methylene chloride (32 ml) cooled in an ice bath was added H 2 SO 4 (13 ml, 343 mmol), dropwise. The reaction was then warmed to room temperature and stirred overnight. After stirring was discontinued, the thick H 2 SO 4 bottom layer was separated, cooled in an ice bath, and then carefully quenched by dropwise addition of concentrated aqueous NH 4 OH over 15 min. The aqueous layer was extracted with methylene chloride (four 70-ml extractions); the combined organic layers were washed with brine (20 ml), dried (Na 2 SO 4 ), and then concentrated in vacuo to afford 3 as thick oil. The oil was triturated with diethyl ether to give a solid, and the ether was removed, in vacuo, to give 3 as a colorless solid (4.56 g, 97%): ϩAPCI MS, m/z 324.4 (MH ϩ ).
Step 3. To a solution of 3 (0.12 g, 0.37 mmol) in methanol (20 ml) was added 20% Pd(OH) 2 on carbon (50% wet; 36 mg). The mixture was placed on a Parr shaker and was reduced (48 psi H 2 ) at room temperature for 1 day. The mixture was filtered through a pad of Celite and then concentrated to give a 2:1 mixture of 4 and mono N-Bn 3 (ratio determined by 1 H NMR in CD 3 OD) as oil (63 mg): ϩAPCI MS, m/z 144.1 (MH ϩ ). The mixture was carried to the following step without further purification.
Step 4. The crude product from step 3 (4) (ϳ0.25 mmol), 6-chloro-9-(4-chlorophenyl)-8-(2-dichlorophenyl)-9H-purine (5) (Griffith et al., 2009 ) (139 mg, 0.37 mmol), and triethylamine (62 l, 0.44 mmol) were combined in ethanol (2.5 ml) and warmed to 60°C for 2 h. The reaction mixture was concentrated and then extracted into methylene chloride from saturated aqueous NaHCO 3 . The organic layers were combined, dried (Na 2 SO 4 ), filtered, evaporated to dryness, and then purified by flash chromatography using 1 to 10% methanol in methylene chloride as eluent to obtain M1 (7) (92.5 mg, 52% from 3) as an off-white solid: ϩESI MS, m/z 482.2 (MH ϩ ) 1 H NMR (400 MHz, CD 3 OD) ␦ ppm 8.22 (s, 1 H), 7.56 -7.61 (m, 1 H), 7.36 -7.48 (m, 5 H), 7.26 -7.31 (m, 2 H), 4.92-5.17 (m, 2 H) , 3.84 (br s, 2 H), 2.18 (ddd, J ϭ 14.1, 10.8, 4.2 Hz, 2H), 1.61 (br d, J ϭ 13.7 Hz, 2H).
Synthesis of M2. 4-Aminopiperidine-4-carboxylic acid (6, 52 mg, 0.36 mmol) and Na 2 CO 3 (59 mg, 0.55 mmol) were combined in water (1 ml).
6-Chloro-9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purine (5) (57.3 mg, 0.152 mmol) was added, and the mixture was heated to reflux overnight. The reaction mixture was cooled, and the resulting solids were collected by filtration, washed with water, and then dried under high vacuum to give to afford M2 (8) (60 mg, 82%) as a colorless solid: ϩESI MS, m/z 483.1 (MH ϩ ); 1 H NMR (400 MHz, DMSO-d 6 ) ␦ ppm 8. 25 (s, 1H), 7.68 -7.71 (m, 2H), 7.44 -7.50 (m, 5H), 7.29 -7.34 (m, 2H) , 2.00 -2.10 (m, 2H), 1.57-1.66 (m, 2H).
Synthesis of M5. 6-Chloro-9-(4-chlorophenyl)-8-(2-dichlorophenyl)-9H-purine (5) (250 mg, 0.666 mmol), piperidine-4-one (9) (102 mg, 0.666 mmol), and triethylamine (0.28 ml, 2.0 mmol) were combined in ethanol (5 ml) and stirred at 60°C for 2.5 h. The reaction mixture was concentrated and then extracted into methylene chloride from saturated aqueous NaHCO 3 . The organic layers were combined, dried (Na 2 SO 4 ), filtered, evaporated to dryness, and then purified by flash chromatography using 0 to 50% ethyl acetate in hexanes as eluent to obtain compound 10 (273 mg, 94%) as a solid: ϩESI MS, m/z 438.1 (MH ϩ ); 1 H NMR (400 MHz, CD 2 Cl 2 ) ␦ 8.38 (s, 1H), 7.51-7.55 (m, 1H), 7.33-7.47 (m, 5H), 7.20 -7.27 (m, 2H) , 4.62 (br s., 4H), 2.59 (t, J ϭ 6.2 Hz, 4H).
Animals, Dosing, and Sample Collection. Intact and bile duct-cannulated rats (200 -270 g) were purchased from Charles River Laboratories (Wilmington, MA). Transgenic mice (CB6F1/Jic-Tg-RasH2 Hemizygous) were obtained from Taconic Farms (Germantown, NY). Beagle dogs (10 -12 kg) were from an in-house colony. Animals were quarantined for a minimum of 3 days before treatment and were maintained on a 12-h light/dark cycle. The animals were housed individually in stainless steel metabolism cages. The animals were fasted overnight before administration of the dose and were fed 6 h after the dose. The animals were provided water ad libitum. All studies were conducted in a research facility accredited by the American Association for the Accreditation of Laboratory Animal Care. All animal studies were approved by the institutional animal care and use committee.
Rats. A group of SD rats (n ϭ 3/gender) were administered a single 30-mg (free base)/kg oral dose of [ 14 C]CP-945,598 for the mass balance study. For biliary excretion experiments, another group of bile duct-cannulated SD rats (n ϭ 2/gender) were administered a single 30 mg/kg oral dose of [ 14 C]CP-945,598 as described above. The dose of [ 14 C]CP-945,598 was formulated in 0.5% methyl cellulose at a target concentration of 6 mg active/ml (ϳ77.9 Ci/ml) on the day before dose administration. The suspension was thoroughly mixed using a magnetic stir bar and plate and by vortexing and sonification.
Each rat received an dose of ϳ102 Ci of radiolabeled material. Urine and feces were collected from intact animals for 7 days at 0 to 8, 8 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 to 168 h after the dose. The first feces sample was collected at 0 to 24 h after the dose. Bile, urine, and fecal samples were collected from bile duct-cannulated animals for 2 days at 0 to 8, 8 to 24, and 24 to 48 h postdose. The weight of each urine, feces, and bile sample was recorded, and all of the biological samples were stored at Ϫ20°C until analysis.
A third group of animals (n ϭ 5/gender) were dosed with 30 mg/kg [ 14 C]CP-945,598 for the identification of circulating metabolites. Blood samples were collected from rats (n ϭ 1/sex/time point) by intracardiac puncture after anesthesia with CO 2 . Terminal blood samples (maximum obtainable) were collected into tubes with no anticoagulant at 1, 2, 4, 8, and 24 h postdose. For pharmacokinetic experiments, a fourth group of jugular vein-cannulated rats (n ϭ 3/gender) were orally dosed with 30 mg/kg [ 14 C]CP-945,598. Blood samples were collected from the jugular vein cannula (JVC) into tubes with no anticoagulant at predose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 , and 96 h postdose. After the collection of the 1-and 8-h blood sample, ϳ2 ml of whole blood from control donor animals were administered via the JVC to maintain blood volume. The 2 ml of whole blood were removed from the donor animal via the JVC by using a syringe and were immediately infused into the recipient animal. There was no anticoagulant added to the donor blood. The blood samples were centrifuged at 2500g for 10 min to obtain the serum. Serum was transferred to clean tubes and stored at Ϫ20°C until analysis.
Mice. A group of nine male and nine female transgenic mice (CB6F1/JicTg-RasH2 Homozygous) were housed in Nalgene metabolic cages (three mice per cage) designed to collect urine and feces. Each animal was administered a single dose of [
14 C]CP-945,598 at a target dose level of 20 mg/kg (800 Ci/kg) via oral gavage. Urine and feces were collected from these animals for 7 days at 0 to 8, 8 to 24, 24 to 48, 48 to 72, 72 to 96, 96 to 120, 120 to 144, and 144 male and three female  mice were collected into tubes with no anticoagulant at predose, 1, 2, 4, 8, 12, 24 , and 48 h postdose. The blood samples were centrifuged at 2050g for 10 min to obtain the serum. Serum was transferred to clean tubes and stored at Ϫ20°C until analysis. Dog Study. One group (group 1) of two male and two female beagle dogs (10 -12 kg) were orally administered a single 5 mg/kg base equivalent dose of [ 14 C]CP-945,598. Another group (group 2) of one male and one female dog were cannulated at the bile duct and administered a 5 mg/kg dose of [ 14 C]CP-945,598. On the day before dosing, each animal was fitted with a jacket. The infusion line was connected to a tether system to initiate continuous infusion of a bile salt replacement solution. Bile salts were administered at the initiation of the predose bile collection and throughout the period of bile collection. The rate of infusion was approximately 0.9 to 1.25 ml/h. The bile salts replacement solution was prepared by addition of ϳ18 g of cholic acid to each 1 liter of 0.9% sodium chloride solution. Sodium bicarbonate (ϳ1.1 g) was added to each 1 liter of solution. The solution was mixed, adjusted to a pH of 7.0 to 7.4, and sterile-filtered through 0.2-m filters into sterile via flex bags. Infusion intervals and volumes administered were recorded.
The dose of [ 14 C]CP-945,598 was formulated at a target concentration of 1.66 mg active/ml (ϳ5 Ci/ml) in 0.5% methyl cellulose on the day before dose administration. The suspension was thoroughly mixed using a magnetic stir bar and plate and by vortexing and sonification. Each animal received 150 Ci of radioactivity. Urine, feces, and cage wash/cage wipes were quantitatively collected from intact animals at Ϫ18 to 0 (predose), 0 to 12, and 12 to 24 h and then at 24-h intervals through 168 h postdose. The first feces and cage wash samples were collected at the 0 to 24 h postdose. Urine, bile, and feces were collected from bile duct-cannulated dogs for 2 days at Ϫ18 to 0 (predose), 0 to 12, 12 to 24, and 24 to 48 h postdose. The weight of each urine, bile, and fecal sample was recorded.
To identify circulating metabolites, a third group of two male and two female dogs (group 3) was administered a single 5 mg/kg oral dose [
14 C]CP-945,598 as described above. Blood samples (3 ml/time point for group 1 and 10 ml/time point for group 3) were collected into serum Vacutainers via a jugular venipuncture at predose and 0. 25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72 , and 96 h postdose for group 1 and at 1, 4, 8, and 12 h postdose for group 3. The blood was allowed to clot at room temperature for at least 30 min and centrifuged (3000g, 15 min, ϳ4°C). Serum was collected into new tubes and stored at Ϫ20°C until analysis.
Determination of Radioactivity. The radioactivity in urine, bile, feces, and serum was determined by liquid scintillation counting. Triplicate aliquots of urine (100 -500 l), bile (50 -100 l), or serum (25-100 l) were mixed with scintillation cocktail (15 ml) for radioanalysis.
The weight of each fecal sample was determined, and the feces were homogenized with water (20% w/w, feces-water) by using a probe-type homogenizer. The total weight of the homogenate was recorded. After homogenization, triplicate aliquots (100 -500 l) were transferred into tared cones and pads, weighed, and dried overnight at ambient temperature before combustion in an automatic sample oxidizer (A0387; PerkinElmer Life and Analytical Sciences). Radioactivity in the combustion products was determined by trapping the liberated CO 2 in Carbo-Sorb (PerkinElmer Life and Analytical Sciences) followed by liquid scintillation counting using Permafluor Eϩ (PerkinElmer Life and Analytical Sciences) as a scintillation cocktail. Combustion efficiency was determined daily before the combustion of study samples, using diluted dose formulation or a 14 C standard. The measured radioactivity content in combusted samples was adjusted using the combustion efficiency values. Samples were analyzed for radioactivity for 2 min (5 or 10 min for serum). Scintillation counter data were automatically corrected for counting efficiency using an external standardization technique and an instrument-stored quench curve generated from a series of sealed quench standards. Radioactivity less than twice the background value was considered to be below the limit of determination. An aliquot of each fecal homogenate was transferred into a separate PETG container and weighed. The aliquots were stored at Ϫ20 Ϯ 5°C until metabolite profiling.
Samples collected before dosing were used as controls and counted to obtain a background count rate. The radioactivity in the dose was established as 100% of the total radioactivity. The radioactivity at each sampling time for urine, bile, and feces was defined as the percentage of dose excreted in the respective matrices. The amount of radioactivity in serum was expressed as nanogramequivalents of parent drug per milliliter and was calculated by using the specific activity of the dose administered.
Extraction of Metabolites from Biological Samples. Serum samples were added to 4 volumes of acetonitrile, vortexed, and sonicated (ϳ10 min). The mixtures were centrifuged at 2530g for approximately 10 min, and the supernatants were placed in clean 50-ml Falcon polypropylene conical tubes. The pellets were extracted with an additional 4 volumes of acetonitrile, the mixtures were centrifuged at 2530g for approximately 10 min, and the supernatants were combined. Aliquots (0.1-0.2 ml) were analyzed by liquid scintillation counting. The mean recovery of radioactivity after extraction was determined to be ϳ90.0%. The supernatants were evaporated to dryness under nitrogen in a TurboVap LV evaporator (Caliper Life Sciences, Hopkinton, MA). The residues were then reconstituted in 0.3 ml of starting mobile phase and centrifuged at 16,000g for 5 min. Aliquots (100 l) were injected onto the HPLC system.
Urine samples from 0 to 12, 12 to 24, and 24 to 48 h intervals were pooled by volume. Pooled urine samples (ϳ2.0 -2.5 ml) were flash-frozen in 15-ml centrifuge tubes and lyophilized overnight. Sample residues were reconstituted in 0.5 ml of water. These solutions were vortexed for approximately 5 min, were transferred to 1.5-ml Eppendorf tubes, and then were centrifuged at 16,000g for approximately 2 min. Aliquots (100 l) of the supernatants were injected onto the HPLC column without further purification. Pooled bile samples (0 -48 h) (100 l) were directly injected onto the HPLC system after centrifugation at 16,000g for approximately 2 min.
Fecal homogenates containing the highest levels of excreted radioactivity (0 -48 h) were pooled. Pooled samples (ϳ2.5 g) were suspended in 20 ml of acetonitrile. Suspensions were sonicated for 15 min, vortexed for 5 min, and shaken in a 37°C water bath for 1 h. After centrifugation (2500g for 10 min), the supernatants were transferred to clean, 50-ml conical tubes, and the residues were further extracted with 15 ml of acetonitrile. Combined supernatants (0.5-1 ml) were counted to determine the extraction efficiency. The mean recovery of radioactivity after extraction was 90.5 to 93.5%. The supernatants were evaporated to dryness under nitrogen in a TurboVap LV evaporator, and the residues were reconstituted in 0.5 ml of the HPLC mobile phase. Aliquots (100 l) of concentrated fecal extracts were injected onto the HPLC column that connected to a ␤-RAM radioactivity monitor.
High-Performance Liquid Chromatography. The HPLC system consisted of an HP-1100 solvent delivery system, an HP-1100 membrane degasser, and an HP-1100 autoinjector (Hewlett Packard, Palo Alto, CA) and a ␤-RAM radioactivity monitor (IN/US Systems, Tampa, FL). Chromatography was performed on a Kromasil C18 column (5 m, 4.5 ϫ 150 mm) with a mobile phase containing a mixture of 5 mM ammonium formate (pH ϭ 3.0) (solvent A) and acetonitrile (solvent B). For urine, bile, and serum of rats and dogs, the mobile phase was initially composed of solvent A/solvent B (80:20). The mobile phase composition was then linearly programmed to solvent A/solvent B (60:40) over 30 min and changed to solvent A/solvent B (50:50) over 8 min. A short gradient was programmed to solvent A/solvent B (20:80) over 2 min, and the mobile phase composition was returned to the starting solvent mixture over 3 min. The system was allowed to equilibrate for approximately 7 min before the next injection was made. The flow rate was 1.0 ml/min, and the separation was achieved at ambient temperature.
For separation of fecal metabolites, the mobile phase was initially composed of solvent A/solvent B (80:20), ramped to 65:35 over 35 min, followed by another ramp to 60:40 over 5 min. A gradient was programmed to solvent A/solvent B (20:80) over 10 min, and the mobile phase composition was returned to the starting solvent mixture over 3 min. The system was allowed to equilibrate for 7 min before the next injection. A flow rate of 1 ml/min was maintained throughout the analysis.
LC-MS/MS. LC-MS/MS was performed on a Finnigan LCQ Deca LC-MS/MS system (Thermo Fisher Scientific) operating with ESI. The effluent from the HPLC column was split, and ϳ50 l/min was introduced into the atmospheric pressure ionization interface. The remaining effluent was directed to the flow cell of the ␤-RAM. The ␤-RAM response was recorded in real time by the mass spectrometer that provided simultaneous detection of radioactivity and mass spectrometry data. The interface was operated at 4500 V, and the mass spectrometer was operated in the positive ion mode.
Quantitative Assessment of Metabolite Excretion. Metabolite quantification was performed by measuring the areas of individually separated HPLC peaks using the ␤-RAM and Laura program (version 3.1.1.39; LabLogic Systems Ltd., Sheffield, UK). The ␤-RAM provided integrated peak representation printouts in counts per minute as well as the percentage of the radiolabeled material. The ␤-RAM was operated in the homogeneous liquid scintillation counting mode with the addition of 3 ml/min of True-Count (IN/US Systems) scintillation cocktail to the effluent after MS detection. Quantitation of circulating metabolites was performed with the LC-accurate radioisotope counting system (AIM Research Company, Hockessin, DE), using the stopflow mode with a 2.2 liquid flow cell. The counting time was 60 s for each 25-s fraction.
Quantitation of CP-945,598 and M1 in Serum. Serum concentrations of CP-945,598 and M1 were determined using a characterized HPLC-MS/MS assay method. Serum samples (25 l) were extracted using a Waters Oasis MCX (10 mg) 96-well solid-phase extraction plate. After washing with 200 l of MeOH followed by 200 l of 0.1 N HCl, loaded samples were eluted with 200 l of methanol-ammonium hydroxide (95:5; v/v). The solutions were dried and reconstituted in 150 l of HPLC mobile phase, and 100 l of reconstitutes were injected onto a Luna C18 column (3 mm, 50 ϫ 4.6 mm; Phenomenex, Torrance, CA) with a binary mixture of 10 mM ammonium acetate, pH 6.8 (solvent A) and acetonitrile (solvent B). The flow rate was 0.5 ml/min, and the separation was achieved at ambient temperature. A gradient program consisting of 20% B from 0 to 0.7 min, 20 to 90% B from 0.7 to 2 min, 90% B from 2 to 4 min, and 90 to 20% B from 4 to 4.2 min was used for the analysis. A Sciex 4000 mass spectrometer was used in multiple reaction monitoring mode. CP-945,598, M1, and internal standard MS/MS ions were monitored at transitions of m/z 510 3 436, 482 3 436 and 517 3 437, respectively. The dynamic range of the assay was 10 to 1000 ng/ml for both analytes.
Pharmacokinetic Analysis. Pharmacokinetic parameters were determined using WinNonlin (version 3.2). Maximum observed concentrations (C max ) of CP-945,598, M1, or total radioactivity (parent drug equivalents) in serum were estimated directly from the experimental data, with t max defined as the time of first occurrence of C max . Terminal phase rate constants (k el ) were estimated using least-squares regression analysis of the serum concentration-time data obtained during the terminal log-linear phase. The half-life (t 1/2 ) was calculated as 0.693/k el . The area under the serum concentration-time curve from time 0 to the last time (t) with a measurable concentration [AUC (0 -t) ] was estimated using the linear trapezoidal rule. AUC from time t to infinity [AUC (t-ϱ) ] was estimated as C est /k el , where C est represents the estimated concentration at time t based on the aforementioned regression analysis. AUC from time 0 to infinity [AUC (0 -ϱ) ] was estimated as the sum of [AUC (0 -t) ] and [AUC (t-ϱ) ] values.
Results

C Excretion. Rats. After a single oral dose of [
14 C]CP-945,598 to SD rats, an overall mean of 97.8% of the total dose was recovered in the urine, feces, and cage wash of the rats over a period of 168 h postdose (Table 1 ). The mean cumulative dose recovered in feces of male and female rats was 93.4 and 94.7%, respectively. The mean cumulative excretion in the urine of male and female rats was 3.38 and 2.53% of the dose, respectively (Table 1) . Approximately 95% of the excreted radioactivity recovery occurred in the first 48 h. There was no gender difference in the routes of excretion of radioactivity.
Mean recoveries of dosed radioactivity from bile duct-cannulated male rats were 3.74% in urine, 22.5% in feces, and 75.0% in bile. Mean recoveries of dosed radioactivity from bile duct-cannulated female rats were 1.65% in urine, 25.5% in feces, and 67.3% in bile. The mean total recoveries were 102 and 95.8%, for male and female bile duct-cannulated rats, respectively (Table 1) . Because Ͻ3% of the radioactivity in feces of intact rats accounted for unchanged drug, it is highly likely that the majority of radioactivity (22.5%/25.5%, male/ female) excreted in feces of bile duct-cannulated rats is probably due to secretion into intestine.
Mice. After a single oral administration of [ 14 C]CP-945,598 to Tg-RasH2 mice, the mean cumulative excretion in urine and feces averaged 99.0 and 96.4% in male and female mice, respectively (Table 1 ). The mean cumulative dose recovered in feces averaged 95.6% in male mice and 93.6% in female mice. The mean cumulative excretion in urine averaged 3.44% in male mice and 2.82% in female mice.
Dogs. After a single oral dose of [ 14 C]CP-945,598 to dogs, a mean of 99.3% of the total dose was recovered in the urine, feces, and cage wash of the dogs (Table 1) . At 168 h after the dose, the cumulative excretion in feces averaged 98.0% in male dogs and 90.6% in female dogs. The cumulative excretion in urine averaged 3.59% in male dogs and 6.44% in female dogs. Approximately 90 and 84.5% of the excreted radioactivity recovery occurred in the first 48 h for male and female dogs, respectively.
Pharmacokinetics. Rats. Mean serum concentration-time curves for unchanged CP-945,598, M1, and total radioactivity are shown in Fig. 3 for both male and female rats, respectively. Mean C max values of CP-945,598, M1, and total radioactivity in males were 1456 ng/ml, 3853 ng/ml, and 12,969 ng-Eq/ml and occurred at 1.3, 2.0, and 2.0 h after oral administration, respectively (Tables 2-4). In female rats, mean C max values for unchanged CP-945,598, M1, and total radioactivity were 2670 ng/ml, 4663 ng/ml, and 13,093 ng-Eq/ml reached at 2.8, 11.3, and 6.7 h, respectively. In male rats, mean half-lives of unchanged CP-945,598, M1, and total radioactivity were 3.6, 6.4, and 31.5 h. In female rats, mean half-lives of CP-945,598, M1, and total radioactivity were 5.0, 4.7, and 31.1 h (Tables 2-4). Mean AUC (0 -ϱ) values of total radioactivity were 128,061 and 242,869 ng-Eq ⅐ h/ml for male and female rats, respectively (Table 4) .
Mice. Mean serum concentration-time curves for unchanged CP-945,598, M1, and total radioactivity are shown in Fig. 4 for both male and female mice, respectively. Mean C max values of unchanged CP-945,598, M1, and total radioactivity in males were 520 ng/ml, 4610 ng/ml, and 9170 ng-Eq/ml and occurred at 1, 2, and 2 h after oral administration, respectively (Tables 2-4) . In female mice, mean C max 
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dmd.aspetjournals.org values for CP-945,598, M1, and total radioactivity were 2130 ng/ml, 5520 ng/ml, and 11,600 ng-Eq/ml reached at 1, 2, and 2 h, respectively. In male mice, mean half-lives of CP-945,598, M1, and total radioactivity were estimated be 2.8, 5.5, and 7.2 h (Tables 2-4) . In female mice, mean half-lives of CP-945,598, M1, and total radioactivity were estimated be 1.8, 3.4, and 7.2 h, respectively. Mean AUC (0 -tlast) values of unchanged CP-945,598, M1, and total radioactivity were 1390 ng-h/ml, 46,500 ng-h/ml, and 143,000 ng-Eq ⅐ h/ml for male mice, respectively. In female mice, mean AUC (0 -tlast) values of CP-945,598, M1, and total radioactivity were 3690 ng-h/ml, 46,100 ng-h/ml, and 139,000 ng-Eq ⅐ h/ml, respectively. Dogs. Mean serum concentration-time curves for unchanged CP-945,598, M1, and total radioactivity are shown in Fig. 5 for both male and female dogs, respectively. The calculated pharmacokinetic parameters for CP-945,598, M1, and total radioactivity are summarized in Tables 2, 3 , and 4, respectively. Mean C max values of CP-945,598, M1, and total radioactivity in males were 819 ng/ml, 766 ng/ml, and 2330 ng-Eq/ml and occurred at 1.0, 1.0, and 1.0 h after oral administration, respectively (Tables 2-4). In female dogs, mean C max values for unchanged CP-945,598, M1, and total radioactivity were 637 ng/ml, 934 ng/ml, and 2250 ng-Eq/ml reached at 0.8, 1.0, and 1.0 h, respectively. In male dogs, mean half-lives of CP-945,598, M1, and total radioactivity were 5.2, 4.0, and 11.1 h. In female dogs, mean half-lives of CP-945,598, M1, and total radioactivity were 5.8, 4.8, and 14.0 h. Mean AUC (0 -ϱ) values for CP-945,598, M1, and total radioactivity were 5790 ng ⅐ h/ml, 5020 ng ⅐ h/ml, and 29,000 ng-Eq ⅐ h/ml for male dogs, respectively. In female dogs, mean AUC (0 -ϱ) values for unchanged CP-945,598, M1, and total radioactivity were 3040 ng ⅐ h/ml, 4870 ng ⅐ h/ml, and 25,700 ng-Eq ⅐ h/ml, respectively.
Metabolic Profiles. Rat urine. Representative HPLC radiochromatograms of urinary metabolites from intact male and female rats are shown in Fig. 6 . The metabolites were quantified by integration of the radiochromatographic peaks. The percentages of urinary metabolites, expressed as administered dose, for male and female rats are shown in Table 5 . A total of 11 metabolites were detected in the chromatograms. All these metabolites were present at Ͻ2% of the dose in both male and female rats.
Rat feces. Representative HPLC radiochromatograms of fecal metabolites from intact male and female rats are shown in Fig. 6 . The percentages of fecal metabolites, expressed as administered dose, for male and female rats are shown in Table 5 . The major metabolites were identified as M1 (10.7 and 7.8%), M2 (14.8 and 34.3%), M5 (2.2 and 2.0%), M6 (11.1 and 8.9%), M9a, 9b, and 9c (9.6 and 6.7%), M10 (7.0 and 8.5%), M14 (3.4 and 1.4%), and M15a, 15b, and 15c (10.1 and 7.1%) of the dose in male and female rats, respectively. M18 was identified only in male rats. The other metabolites (M3, M7, M22, M23, M25, and M26) each were present at Ͻ2% of the dose.
Rat bile. Representative HPLC radiochromatograms of biliary metabolites from male and female rats are shown in Fig. 7 . Parent compound and 12 (male) and 6 (female) metabolites were detected in the chromatograms. The percentages of biliary metabolites, expressed as dose, for male and female rats are shown in Table 6 . There were qualitative and quantitative differences in the biliary metabolic profile of the male and female rats. The major metabolites identified in the bile were M2 (19.7 and 42.1%), M3 (6.5 and 1.4%), M4 (8.8 and 6.8%), and M6 (4.7 and 1.4%) of the dose for male and female rats, respectively. The other metabolites were each present at Ͻ4% of the dose. M11, M13, M17, M19, M21, and M24 were detected only in the bile of male rats. Rat serum. Representative HPLC radiochromatograms of circulating metabolites at 4 h postdose from male and female rats are shown in Fig. 7 . Parent compound and six metabolites were detected in the chromatograms. The percentages of circulating metabolites are shown in Table 7 . The major metabolites identified in the serum of rats were M1, M3, and M4 at all time points.
Mouse urine. A representative HPLC radiochromatogram of urinary metabolites from a male mouse is shown in Fig. 8 . The mean percentage of metabolites in relation to the administered dose excreted in feces of male and female mice is shown in Table 8 . A total of 7 metabolites were detected in mouse urine. The metabolites were identified as M1 (0.3%), M2 (1.1%), M3 (0.2%), M4 (0.2%), M14 (0.2%), and M20 (0.2%).
Mouse feces. A representative HPLC radiochromatogram of fecal metabolites from one male mouse is shown in Fig. 8 . A total of 16 metabolites were detected in mouse feces. Mean percentages of metabolites in relation to the administered dose excreted in feces of mice are shown in Table 8 . Five metabolites, M1, M2, M3, M6, and M12, constituted the major peaks in the radiochromatogram and accounted for 18.7, 29.9, 5.3, 10.6, and 10.2% of the dose, respectively. The other 11 identified metabolites (M4, M5, M9a, M9b, M9c, M14, M15a, M15b, M20, M22, and M26) each were present at Ͻ5% of the dose.
Mouse serum. The HPLC radiochromatograms of circulating metabolites from serum at 4 and 12 h postdose from one male mouse are shown in Fig. 9 . A total of nine metabolites were detected in the chromatograms. The percentages of circulating metabolites for male and female mice are shown in Table 7 . The metabolites were identified as unchanged CP-945,598 (2.1 and 2.6%), M1 (58.9 and 50.7%), M2 (2.5 and 1.7%), M3 (14.2 and 11.9%), M4 (10.3 and 10.5%), M5 (1.3 and 2.1%), M6 (1.8 and 1.7%), M9 (1.2 and 2.2%), M20 (0.7 and 1.6%), and M26 (3.3 and 9.7%) of the circulating radioactivity at 4 and 12 h postdose, respectively. Dog urine. A representative HPLC radiochromatogram of urinary metabolites from one female dog is shown in Fig. 10 . The mean percentages of urinary metabolites in relation to the administered dose excreted in urine of male and female dogs are shown in Table 9 . A total of four (male) and four (female) radioactive peaks were observed in the dog urine. These were identified as CP-945,598 (0.15%), M1 (0.1%), M2 (1.3%), M6 (1.0%), and M7 (0.2%).
Dog feces. A representative HPLC radiochromatogram of fecal metabolites from a male dog is shown in Fig. 10 . Parent CP-945,598 and nine metabolites were detected in dog feces. The mean percentage of metabolites in relation to the administered dose excreted in feces of male and female dogs is shown in Table 9 . Metabolites M2 and M6 constituted the major peaks in the radiochromatogram and accounted for 28.3 and 32.9% of the dose, respectively. The other metabolites were identified as M1 (9.9%), M3 (2.2%), M4 (1.8%), M5 (1.3%), M7 (4.7%), M21 (2.2%), and M22 (1.9%).
Dog bile. A representative HPLC radiochromatogram of biliary metabolites from one male dog is shown in Fig. 11 . Parent compound and five (male) and six (female) metabolites were observed in the dog bile. The percentages of biliary metabolites, expressed as dose, for male and female dogs are shown in Table 6 . The major metabolites identified in the bile were M1 (5.4 and 1.3%), M2 (22.3 and 5.2%), M4 (2.7, and 0.2%), M6 (15.9 and 3.7%), and M17 (6.2 and 1.3%) of the dose. (Table 10) . The ion at m/z 465 was due to the loss of NH 3 .
The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unchanged. M1 had an identical spectrum and coeluted with the synthetic standard of a desethyl metabolite. On the basis of these data, M1 was identified as 4-amino-1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)piperidine-4-carboxamide. Metabolite M2. M2 was detected in all species. M2 showed a protonated molecular ion at m/z 483, 27 Da lower than the parent compound, suggesting a cleaved product. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 422, 436, 438, 448, and 466 (Table 10) . The ion at m/z 466 resulted from the loss of NH 3 . The ion at m/z 422, loss of 44 Da from the fragment at m/z 466, suggested the presence of a carboxylic acid moiety. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unmodified. M2 had an identical spectrum and coeluted with a synthetic standard of a carboxylic acid. On the basis of these data, M2 was identified as 4-amino-1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)piperidine-4-carboxylic acid.
Metabolite M3. M3 was detected in the excreta of all species and the serum of rats and mice. M3 displayed a protonated molecular ion at m/z 498, 16 Da higher than M1, suggesting that a single oxidation had occurred to the molecule. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 410, 420, 422, 436, 453 , and 465 (Table 10) . The ion at m/z 465 resulted from loss of the hydroxylamine. The ion at m/z 453 was produced by deamidation on the piperidine ring. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unsubstituted. On the basis of these data, M3 was identified as 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-hydroxyamino-piperidine-4-carboxylic acid amide. Metabolite M4. M4 was found in rat and dog bile, mouse urine and feces, and the serum of all species. It showed a protonated molecular ion at m/z 453, 57 Da lower than the parent compound, suggesting that M4 was a cleaved product. Its MS 2 and MS 3 spectra showed fragment ions at m/z 320, 329, 339, 356, 368, 382, 383, and 435 (Table 10) . The ion at m/z 435 resulted from the loss of one water molecule. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unchanged. Incubation of 1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)piperidin-4-one (M5) with hydroxylamine in an ammonium acetate buffer (pH ϭ 4) produced a substance that had a identical MS 2 spectrum and a retention time on HPLC similar to that of M4. On the basis of these data, M4 was identified as 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-piperidin-4-one oxime.
Metabolite M5. M5 was detected in the feces and serum of all species. M5 showed a protonated molecular ion at m/z 438. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, and 420 (Table 10 ). The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unchanged. M5 had an identical MS 2 spectrum and coeluted with a synthetic standard of 1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)piperidin-4-one. On the basis of these data, M5 was identified as 1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)piperidin-4-one.
Metabolite M6. M6 was detected in all species. It displayed a protonated molecular ion at m/z 498, 16 Da higher than metabolite M1. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 418, 437, 446, 463, 480, and 481 (Table 10) . The ions at m/z 481 and 480 resulted from loss of NH 3 and one molecule of water, respectively, from the parent molecule. The ion at m/z 463 resulted from the loss of NH 3 followed by a subsequent loss of one water molecule. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was not modified. On the basis of these data, M6 was tentatively identified as the hydroxyl-4-amino-1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)piperidine-4-carboxamide.
Metabolite M7. M7 was detected in rat urine and dog urine and feces. M7 showed a protonated molecular ion at m/z 514, 32 Da higher than metabolite M1, suggesting the addition of two oxygen atoms to M1. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 418, 446, 463, 479, and 497 (Table 10) . The ion at m/z 497 resulted from the loss of NH 3 . The prominent ion at m/z 463 was derived from sequential losses of NH 2 OH and H 2 O from the protonated molecular ion. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was not substituted. On the basis of these data, M7 was tentatively identified as dihydroxy-4-amino-1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)piperidine-4-carboxamide.
Metabolite M8. M8 was found only in female rat feces. It displayed a protonated molecular ion at m/z 630, 120 Da higher than the parent drug, suggesting that it was a conjugate. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 418, 446, 463, 498, 569, 576, 594, and 612 (Table 10) M8 was a ribose conjugate. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unchanged. On the basis of these data, M8 was tentatively identified as the ribose conjugate of hydroxy-4-amino-1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)piperidine-4-carboxamide.
Metabolites M9a, M9b, and M9c. M9a, M9b , and M9c were detected in the feces of rat and mouse. They all displayed a protonated molecular ion at m/z 614, suggesting that they were regioisomers. Their MS 2 and MS 3 spectra were similar and showed fragment ions at m/z 356, 368, 418, 436, 446, 463, 482, 536, 560, 578, and 596 (Table  10) . The ions at m/z 596, 578, and 560 resulted from the consecutive losses of three H 2 O molecules. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unchanged. The ion at m/z 482 resulted from loss of 132 Da from the protonated molecular ion, suggesting that M9a, M9b, and M9c were ribose conjugates of M1. M9a, M9b, and M9c were generated by reaction of M1 with D-ribose in 0.1 N NaOH medium overnight in a water bath; the reaction mixture contained three chromatographic peaks that had the same retention times as M9a, M9b, and M9c and MS 2 and MS 3 spectra similar to those of M9a, M9b, and M9c. On the basis of these data, M9a, M9b, and M9c were identified as regioisomers of ribose conjugates of M1.
Metabolite M10. M10 was found in rat feces. It displayed a protonated molecular ion at m/z 615, 132 Da higher than M2, suggesting that it was a conjugate of M2. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 436, 461, 463, 489, 506, 536 , and 578 (Table 10) . The ion at m/z 597 resulted from the loss of a molecule of H 2 O. The diagnostic ions at m/z 356 and 368, similar to those of parent compound, suggested that the dichlorophenyl purine moiety was unchanged. The ion at m/z 483, 132 Da lower than the protonated molecular ion, suggested that M10 was a ribose conjugate of M2. M10 was generated by reaction of M2 with D-ribose in 0.1 N NaOH medium. The reaction mixture contained one chromatographic peak that had the same retention time as M10 and MS 2 and MS 3 spectra similar to those of M10. On the basis of these data, M10 were identified as the ribose conjugate of M2.
Metabolite M11. M11 was found only in male rat bile. It showed a protonated molecular ion at m/z 686, 176 Da higher than CP-945,598, (Table 10) . The ion at m/z 510, a characteristic loss of 176 Da, suggested that M11 was a glucuronide conjugate. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unsubstituted. On the basis of these data, M11 was tentatively identified as the glucuronide conjugate of CP-945,598.
Metabolite M12. M12 was detected only in the mouse feces and serum. It showed a protonated molecular ion at m/z 644. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 436, 463, 465, 482, 524, 608, and 626 (Table 10) . The ions at m/z 626 and 608 resulted from the consecutive losses of two H 2 O molecules. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unchanged. The MS 3 spectrum of m/z 482 was identical to the MS 2 spectrum of M1. On the basis of these data, M12 was identified as a glucose conjugate of M1. Metabolite M13. M13 was found only in rat bile. It showed a protonated molecular ion at m/z 532. Its MS 2 spectrum showed fragment ions at m/z 356, 398, 496, and 514 (Table 10) . The ions at m/z 514 and 496 resulted from the consecutive losses of two H 2 O molecules. The ion at m/z 356, loss of 176 Da, suggested that M13 was a glucuronide conjugate. On the basis of these data, M13 was identified as a glucuronide conjugate of 9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-ylamine.
Metabolite M14. M14 was detected in the urine and feces of rats and mice. It showed a protonated molecular ion at m/z 356. Its MS 2 spectrum showed fragment ions at m/z 279, 320, and 339 (Table 10) . On the basis of these data, M14 was identified as 9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-ylamine.
Metabolites M15a, M15, and M15c. M15a, M15b, and M15c were found in rat and mouse feces. They showed a protonated molecular ion at m/z 596. Their MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 436, 461, 463, 489, 506, 536, and 578 (Table 10) . The ions at m/z 578 and 560 resulted from consecutive loss of two water molecules. The ion at m/z 506 resulted from the cleavage across the dehydro ribose ring; a subsequent deamidation from the ion at m/z 506 produced a fragment at m/z 463. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unsubstituted. On the basis of these data, M15a, M15b, and M15c were tentatively identified as the regioisomeric dehydro ribose conjugates of M1.
Metabolite M16. M16 was found only in female rat feces. It showed a protonated molecular ion at m/z 466. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 420, 430, and 448 (Table 10) . The ion at m/z 448 resulted from the loss of a H 2 O molecule; a further loss of CO from that produced the ion at m/z 420. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unsubstituted. On the basis of these data, M16 was tentatively identified as the 1-[9-(4- (Table 10 ). The prominent ion at m/z 498, loss of 176 Da, suggested that M17 was a glucuronide conjugate. The ion at m/z 629 was due to deamidation similar to that of the parent drug. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unchanged. On the basis of these data, M17 was tentatively identified as a glucuronide conjugate of M3.
Metabolite M18. M18 was found in rat urine and feces. It showed a protonated molecular ion at m/z 548. Its MS 2 and MS 3 spectra showed fragment ions at m/z 320, 354, 356, and 372 (Table 10) . The ion at m/z 372, 176 Da lower than the protonated molecular ion, suggested that M18 was a glucuronide conjugate. The ion at m/z 372, 16 Da higher than that of M14, suggested that a single oxidation had occurred on the 9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-ylamine moiety. On the basis of these data, M18 was tentatively identified as a glucuronide conjugate of N- [9-(4-chlorophenyl) 
Metabolite M19. M19 was found in rat bile. M19 showed a protonated molecular ion at m/z 469, 16 Da higher than M4. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 433, and 451 (Table 10) . The ion at m/z 451 and 433 resulted from consecutive loss of H 2 O. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unchanged. On the basis of these data, M19 was tentatively identified as 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-hydroxy-piperidin-4-one oxime.
Metabolite M20. M20 was found in rat urine and mouse urine, feces, and serum. It showed a protonated molecular ion at m/z 372, 138 Da lower than unchanged drug, suggesting that M20 was a cleaved product. Its MS 2 and MS 3 spectra showed fragment ions at m /z 190, 292, 319, 320, 337, 354, and 355 (Table 10) . The ion at m/z 354 resulted from the loss of H 2 O. On the basis of these data, M20 was tentatively identified as N- [9-(4-chlorophenyl)-8-(2- 
Metabolite M21. M21 was found in rat urine and bile and dog feces. M21 showed a protonated molecular ion at m/z 501, 18 Da higher than M2. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 437, 465, and 483 (Table 10) . The ion at m/z 483 and 465 resulted from consecutive losses of two water molecules. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the modification had occurred on the piperidine moiety. On the basis of these data, M21 was tentatively identified as 2-amino-4-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-ylamino]-2-(2-hydroxy-ethyl)-butyramide.
Metabolite M22. M22 was found in feces of all species. It showed a protonated molecular ion at m/z 524, 14 Da higher than the unchanged drug, suggesting an addition of one oxygen atom with subsequent loss of two hydrogen atoms. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 382, 466, 479, and 507 (Table 10) . The ion at m/z 507 resulted from the loss of an NH 3 . The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unchanged. On the basis of these data, M22 was tentatively identified as 1-[9-(4- (Table 10) . The ion at m/z 481 resulted from the loss of an NH 3 . The ions at m/z 372 and 384, 16 Da higher than those observed for the parent drug, suggested that one oxygen atom had been added to the dichlorophenyl purine moiety. On the basis of these data, M23 was tentatively identified as hydroxy-M1.
Metabolite M24. M24 was found only in rat bile. It showed a protonated molecular ion at m/z 485. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 441, and 467 (Table 10) . The ion at m/z 467 resulted from the loss of H 2 O. The ion at m/z 441, 44 Da lower than the protonated molecular ion, suggested the presence of a carboxylic acid moiety. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unchanged. On the basis of these data, M24 was tentatively identified as 5-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-ylamino]-3-hydroxyimino-pentanoic acid.
Metabolite M25. M25 was found only in rat urine and feces. It showed a protonated molecular ion at m/z 526, 16 Da higher than parent drug, suggesting that one oxygen atom had been added to the molecule. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, 446, 463, 465, 491, and 509 (Table 10) . The ion at m/z 509 resulted from the loss of an NH 3 ; subsequent loss of H 2 O produced the ion at m/z 491. The ion at m/z 508 resulted from loss of a water molecule; subsequent deamidation produced the ion at m/z 463. The diagnostic ions at m/z 356 and 368, similar to those of parent compound, suggested that the dichlorophenyl purine moiety was unchanged. On the basis of these data, M25 was tentatively identified as hydroxy-1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide.
Metabolite M26. M26 was found only in rat urine and feces and mouse feces and serum. It showed a protonated molecular ion at m/z 428. Its MS 2 and MS 3 spectra showed fragment ions at m/z 356, 368, and 410 (Table 10) . The ion at m/z 410 resulted from the loss of an H 2 O. The diagnostic ions at m/z 356 and 368, similar to those of the parent compound, suggested that the dichlorophenyl purine moiety was unchanged. On the basis of these data, M26 was tentatively identified as 4-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-ylamino]-butan-1-ol.
Discussion
This study reports the comparative disposition and in vivo metabolic profiles of [ 14 C]CP-945,598 in rats, Tg-RasH2 mice, and dogs, animal species used for long-term safety and carcinogenicity testing. [ 14 C]CP-945,598 labeled at the C-8 position of the purinyl moiety, was administered orally to SD rats, Tg-RasH2 mice, and beagle dogs. The administered radioactive dose was quantitatively recovered in all species (rats, 97.8%; dogs, 99.3%; and mice, 97.7%) . Excretion of the radioactivity was rapid and nearly complete within 48 h after dosing in all species. The majority of the dose was excreted in feces in rats (94.1%), dogs (94.3%), and mice (94.6%). In separate studies using bile duct-cannulated rats and dogs, 71.2 and 56.9% of the administered radioactivity was recovered in the bile. This suggested that a major portion of the dose excreted in the feces of rats and dogs was mainly due to biliary excretion rather than to unabsorbed dose.
There were no discernible gender differences in the excretion pattern of radioactivity in these species after oral administration of [ 14 C]CP-945,598. However, the pharmacokinetics of unchanged CP-945,598, its major circulating metabolite M1 and total radioactivity displayed distinct gender-related differences in male and female rats but not in mice and dogs. The exposure (C max and AUC) of CP-945,598, M1, and total radioactivity was higher in females than in males. On the basis of AUC values, the majority of the circulating radioactivity was attributable to metabolites. The parent compound accounted only for 11.1, 16.1, and 1.80% of the total serum radioactivity in rats, dogs, and mice, respectively. In addition, the t 1/2 values of total radioactivity were 7-, 2.3-, and 3.1-fold greater than the t 1/2 of the parent compound in rats, dogs, and mice, respectively, suggesting that one or more of the metabolites circulated for a longer time in these species.
The urine and/or bile radiochromatograms from rats, dogs, and mice indicate that CP-945,598 is extensively metabolized, because Ͻ2.5% of the administered dose was excreted unchanged in the urine or bile. The major portion of administered radioactivity was excreted in urine and bile as the products of oxidation, amide hydrolysis, and conjugation pathways and a combination of these pathways. There were notable species-related qualitative and quantitative differences in 614: 596, 578, 560, 482, 463, 436, 382 596: 578, 536, 463, 446, 418, 368, 356 2204 MIAO ET AL.
dmd.aspetjournals.org Fig. 1 . The primary metabolic pathways of CP-945,598 involved Ndeethylation to form an N-desethyl metabolite (M1) and oxidation of the ethyl group (M25). M1 was subsequently metabolized by amide hydrolysis (M2), oxidation (M3, M6, and M23), and conjugation with ribose (M9a, M9b, and M9c) to form numerous novel and unusual metabolites. The minor metabolic pathways were due to oxidation on the piperidine ring (M22) and glucuronidation (M11). The other metabolites were due to a combination of these primary pathways.
The major circulating and excretory metabolites in rats, dogs, and mice were species-dependent; however, several common metabolites were observed in more than one species (e.g., M1, M2, M3, M4, M5, M9a, M9b, M9c, and M22). The major components of drug-related material in rat excreta were identified as the N-desethyl metabolite (M1, 9.3%), piperidine-4-carboxylic acid (M2, 24.7%), hydroxypiperidine-4-carboxamide (M6, 11.2%), and ribose conjugates (M9a, M9b, and M9c, total combined, 8.8%). M1 was further metabolized by combination of both oxidative and conjugative pathways to form metabolites M3, M4, M5, M7, M17, and M23. Multiple oxidations of M6 formed several unusual piperidine-cleaved metabolites (M13, M14, M18, M20, and M26). Three major circulating metabolites, M1, M3, and M4, were detected at 2, 4, and 8 h postdose in male and female rats.
The major oxidative metabolites in dog excreta were due to multiple oxidations to form the N-desethyl (M1, 10%), piperidine-4-carboxylic acid (M2 29.5%), hydroxypiperidine-4-carboxamide (M6, 33.8%), hydroxyamino-piperidine-4-carboxamide (M3, 2.2%), and piperidine ring scission (M26, 1-9%) metabolites. M3 was further metabolized to form the unusual metabolite M4 (1.8%) and M5 (1.3%). Three major circulating metabolites were identified as M1, M2, and M6 in both male and female dogs.
Of all the drug-related materials, M1 and M2 comprised the greatest abundance at 18.9 and 31.0% of the dose, respectively, in mice excreta. Metabolites M6 and M9 (glucose conjugate of M1), both in feces, were present at 10.6 and 10.2% of the dose, respectively. All other excretory metabolites were present at less than 6% of dose and included M3, M, M5, M6, M13, M17, and M22. The major circulating metabolites in mice include M1, M3, M4, and M26, which ranged from 25 to 47% of total radioactivity. CP-945,598 comprised only Ͻ3% of total circulating radioactivity in both males and females.
Gender differences were apparent in the quantitative and qualitative nature of the excreted metabolites of CP-945,598 in rats. Metabolites M18 and M23 were present only in male rats, whereas M8 (ribose conjugate of M6) and M16 (des-amino of M2) were identified only in female rats. The metabolite M2 was Ͼ2-fold higher in bile and feces of female rats than in that of males. The relative amounts of parent compound and metabolites were higher in female serum than those in males. Gender-related differences in drug metabolism, especially in the rat, have been reported for numerous drugs and occur in both phase I and phase II metabolism (Gradolatto et al., 2005; Anari et al., 2006; Prakash et al., 2007a Prakash et al., ,b, 2008 . One factor commonly known to contribute to gender-and species-dependent metabolism is differential expression of drug metabolism enzymes, especially cytochrome P450 isoforms (Martignoni et al., 2006; Richert et al., 2008) . In this study, several novel and unusual oxidative metabolites (M4, M5, M14, M16, M19, M24, and M26) and ribose conjugates (M8, M9a, M9b, M9c, M12, M115a, M15b, and M15c), formed by multiple pathways (N-dealkylation, oxidation, glucosylation, and ribosylation), were identified. Although similar biotransformation of amino acids has been reported in higher plants, the formation of M4 in mammals is novel and to our knowledge has not been reported previously. N-Hydroxytyrosine and p-hydroxyphenylacetaldehyde oxime has been formed as the early intermediates in the biosynthesis of the tyrosine-derived cyanogenic glucoside dhurrin in microsomal preparations obtained from etiolated seedlings of sorghum (Halkier et al., 1989) . It has also been reported that two Arabidopsis cytochrome P450 enzymes, CYP79B2 and CYP79B3, are involved in the metabolism of tryptophan to an important intermediate, indole-3-acetaldoxime, implicated in auxin biosynthesis (Zhao et al., 2002) . The mechanism of the formation of these acetaldehydes oxime involves decarboxylation and subsequent dehydrogenation (Halkier et al., 1989; Zhao et al., 2002) . The mechanism and the enzyme(s) involved for the formation of M4 are not known at this time. However, incubation of M2 in rat liver S9 and microsomes did not generate M4, whereas incubation of M1 in these preparations produced M3 (hydroxylamine) and M4 (data not shown). These data suggest that M4 is not formed by decarboxylation of M2 but more likely by deamidation of M1 or M3 (N-hydroxy-M1). M5 is formed by nonenzymatic hydrolysis of M4.
N-Hexoside conjugates (N-glucosides and N-ribosides), although rare but not unprecedented, were identified in rats and mice. NGlucosylation of xenobiotics in mammals has been observed for a limited number of drugs such as phenobarbital (Soine et al., 1994; Paibir et al., 2004), 4-(5-pyridin-4-yl-1H-[1,2,4] triazol-3-yl)pyridine-2-carbonitrile (FYX-051) (Nakazawa et al., 2006) and 5-aminosalicylic acid (Tjornelund et al., 1991) , but to our knowledge, Nribosylation has not been reported previously. These ribose conjugates were detected only in feces and not observed in bile; therefore, it is likely the formation of these metabolites was due to gut microbial metabolism.
In conclusion, the results of this study provide the first analysis of formation and excretion of metabolites of CP-945,598 in rats, mice, and dogs, the species used for long-term safety and carcinogenicity studies. It is extensively metabolized in all species after oral administration and the radioactive dose is excreted mainly in feces via bile. It is eliminated by oxidation followed by conjugation. The major circulating and excretory metabolites in rats, mice, and dogs were species-dependent; however, several common metabolites were observed in more than one species. There were also notable genderrelated differences in pharmacokinetic and metabolic behavior in rats. Finally, the identification of these metabolic pathways of 598 in preclinical studies will aid us in understanding its metabolism in humans.
